DOCSLIB.ORG

UCT Unacceptable Medications – Medicare Supplement Applicants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
UCT Unacceptable Medications – Medicare Supplement Applicants The Order of United Commercial Travelers of America • A Fraternal Benefit Society 1801 Watermark Drive, Suite 100, P.O. Box 159019, Columbus, OH 43215 Tel: 614.487.9680 • Toll-free: 800.848.0123 • Fax: 800.948.1039 • www.uct.org UCT Unacceptable Medications – Medicare Supplement Applicants taking any of the medications listed below will be declined if they are not in the open enrollment period. Do not submit their applications. This list is intended for use as a basic guide only. Due to the rapid advances being made in the medical field, it is not possible to include all unacceptable medications or to keep this list updated. UCT has the right to decline applications based on conditions indicated by other medications that are not on this list. Contact the Customer Service Department at (800) 848-1124, ext. 300, or at [email protected], with specific questions. A Azmacort (Triamcinolone) Cisplatin (Platinol) Abilify (Aripiprazole) AZT (Azidothymid) Clomipramine (Anafranil) Abacavir (Ziagen) Azulfidine (Sulfasalazine) Clozapine (Clozaril) Actraphane (Insulin) Clozaril (Clozapine) Actrapid (Insulin) B Cogentin (Benztropine) Adriamycin (Doxorubicin) Baclofen (Kemstro, Lioresal) Cognex (Tacrine) Adrucil (Flourouracil) Baphen Combivir (Zidovudine, Retrovir) Agenerase (Amprenavir) Bendopa (Dopa, Levodopa) Copaxone (Glatiramer) Akineton (Biperiden) Benztropine (Cogentin) Compazine (Prochlorperazine)–if Alfa Epogen (Epogen, Procrit, Beta interferon (Avonex, used for psychotic disorders Epoetin) Betaseron) Cortisone (Cortone)–if used for Alkeran (Melphalan) Betaseron (Beta interferon) arthritis or chronic lung Altretamine (Hexalen) Bicalutamide (Casodex) disorders Amantadine (Symadine, Biperiden (Akineton) Cosmegan (Dactinomycin) Symmetrel) Blenoxane (Bleomycin) Crixivan (Indinavir) Ambenonium Chloride (Mytelase) Bleomycin (Blenoxane) Cyclophosphamide (Cytoxan, Amprenavir (Agenerase) Bromocriptine (Parlodel)–if used Neosar) Anafranil (Clomipramine) for Parkinson’s Cycrimine (Pagitane) Anastrozole (Arimidex) Budesonide (Pulmicort) Cycrimine Hydrochloride Antabuse (Disulfiram) Busulfan (Myleran) (Kemadrin) Arava(Leflunomide) Byetta Cytarabine (Cytosar) Aricept (Donepezil) Cytosar (Cytarabine) Arimidex (Anastrozole) C Cytoxan (Cyclophosphamide, Aripiprazole (Abilify) Calcimar (Calcitonin) Neosar) Aromasin (Exemestane) – taking Calcitonin (Calcimar) for 5 years Capecitabine (Xeloda) D Arsenic Trioxide (Trisenox) Carbidopa (Lodosyn) Dactinomycin (Cosmegan) Artane (Trihexyphenidyl, Tremin) Carbidopa-levidopa (Sinemet) Dantrium (Dantrolene) Atamet (L-Dopa, Levodopa, Casodex (Bicalutamide) Dantrolene (Dantrium) Sinemet) CeeNu (Lomustine) Daunorubicin (Cerubidine) Auranofin (Ridaura, Oral Gold) Cellcept (Mycophenolate Mofetil) Deapril (Eegoloid Mesylates) Avinza (Morhine) Cerespan Delavirdine (Rescriptor) Avonex (Beta interferon, Cerubidine (Daunorubicin) Deponit (Minitran, Nitro Patch, Interferon Beta 1a, Rebif)) Chlorambucil (Leukeran) Nitroglycerin, Nitro-Dur, Azathioprine (Imuran) Chlorpromazine (Thorazine) Nitrostat) Azidothymid (AZT) Cilostazol (Pletal) Didanosine (Videx) ___________________________________________________________________________________________________________________________________ This list is not conclusive and is subject to change at any time without notice. We have the right to decline based on medications not on this list. We do not take anyone using opiate medication(s). Page 1 Rev. 12/13 The Order of United Commercial Travelers of America Didronel (Etidronate) if used for Fluphenazine Hydrochloride Idarubicin (Idamycin) Paget’s (Prolixin) Iletin (Insulin) Dihdroergotoxine (Niloric) Flutamide (Eulexin) Imdur (Isobid, Isordil, Isosorbide) Disulfiram (Antabuse) Fluvoxamine (Luvox) Imuran (Azathioprine) Dolophine (Methodone) Fortovase (Invirase, Saquinavir) Indinavir (Crixivan) Donepezil (Aricept) Foscarnet (Foscavir) Infliximab(Remicade) Dopar (Levadopa, Bendopa) Foscavir (Foscarnet) Initard (Insulin) Doxil (Doxorubicin) FUDR (Floxuridine, FDUR) Interferon Beta-1a (Avonex, Rebif) Doxorubicin (Adriamycin, Doxil, Fulvestrant (Faslodex) Insulin (Actraphane, Actrapid, Rubex) Humulin, Humalog, Hypurin, Dronabinol (Marinol) G Iletin, Initard, Isophane, D4T (Stavudine, Zerit) Galantamine (Razadyne, Reminyl) Isulatard, Lantus, Lentard, Gallium Nitrate (Granite) Lispro, Mixtard, Monotard, E Ganite (Gallium Nitrate) Novolin, Protophane, Pur-In Edophonium Chlorides Gemtuzumab Ozogamicin Mix, PZI, Semitard, Ultralente, Efavirenz (Sustiva) (Mylotarg) Ultratard, Velosulin) Efudex (Fluoroplex, Fluorouracil) Geodon (Ziprasidone) Intron Eldepryl (Selegiline) Gerimal (Salac) Invirase (Saquinavir, Fortovase) Emcyt (Estramustine) Glatiramer (Copaxone) Isobid (Imdur, Isordil, Isosorbide,) Enbrel (Etanercept) Gold Shots (Myochrysine) Isordil (Imdur, Isobid, Isosorbide) Enlon (Reversol, Tensilon) Goserelin (Zoladex) Isophane (Insulin) Epivir (Lamivudine) Isosorbide (Imdur, Isordil, Isobid) Epoetin (Epogen, Procrit, Alfa H Isulatard (Insulin) Epogen) Haldol (Haloperidol) Epogen (Alfa epogen, Procrit) Haloperidol (Haldol) K Ergamisol (Levamisole) Herceptin (Trastuzumab) Kaletra (Lopinavir, Ritonavir, Ergoloid Mesylates (Deapril) Hexalen (Altretamine) Norvir) Eskalith (Lithobid, Lithium) Hivid (Zalcitabine) Kemadrin (Procyclidine Estramustine (Emcyt) Humulin (Insulin) Hydrochloride, Hydrochloride Etanercept (Enbrel) Humalog (Insulin) Pagitane) Etidronate (Didronel) if used for Hydergine (Ergoloid Mesylates) Kemstro (Baclofen, Lioresal) Paget’s Hydrea (Hydroxyurea) Etoposide (VePesid) Hydrochloride Pagitane L Eulexin (Flutamide) (Kemadrin, Procyclidine Lamictal (Lamotrigine) Exelon (Rivastigmine) Hydrochloride) Lamivudine (Epivir) Exemestane (Aromasin) taking for Hydrocortisone (Hydrocortone)–if Lamotrigine (Lamictal) 5 years used for arthritis or chronic lung Lantus (Insulin) disorders Larodopa (L-dopa, Atamet, F Hydroxychloroquine (Plaquenil) Sinemet, Levodopa) Fareston (Toremifene) Hydroxyurea (Hydrea) L-Dopa (Levodopa, Atamet, Faslodex (Fulvestrant) Hyoscyamine (Levsin, Levbid, Sinemet, FDUR (Floxuridine, FUDR) Levsinex) – if used for Larodopa) Femara (Letrozole) Parkinson’s Leflunomide(Arava) Filgrastim (Neupogen) Hypurin (Insulin) Lentard (Insulin) Floxuridine (FUDR, FDUR) Letrozole (Femara) Fluoroplex (Efudex, Fluorouracil) I, J Leukeran (Chlorambucil) Fluorouracil (Efudex, Fluoroplex) Idamycin (Idarubicin) Leuprolide (Lupron) ___________________________________________________________________________________________________________________________________ This list is not conclusive and is subject to change at any time without notice. We have the right to decline based on medications not on this list. We do not take anyone using opiate medication(s). Page 2 Rev. 12/13 The Order of United Commercial Travelers of America Levamisole (Ergamisol) Minitran (Deponit, Nitro Dur, Nolvadex (Tamoxifen) taking for 5 Laviamsole Nitroglycerin, Nitro patch, years Levbid (Hyoscyamine, Levsin, Nitrostat) Norvir (Ritonavir, Kaletra, Levsinex – if used for Mirapex (Pramipexole Lopinavir) Parkinson’s Dihydrochloride) Novolin (Insulin) Levodopa (Bendopa, Dopar) Mithracin (Plicamycin) Levsin (Levbid, Levsinex) Mitomycin (Mutamycin) O (Hyoscyamine)– if used for Mitotane (Lysodren) Olanzapine (Zeprexa) Parkinson’s Moban (Molindone) Oncovin (Vincristine) Lioresal (Kemstro, Baclofen) Molindone (Moban) Oral gold (Ridaura, Auranofin) Lispro (Insulin) Monotard (Insulin) Oreton (Methyltestosterone) Lithane (Lithium) Morphine (Avinza) Oxycodone (Oxycontin) Lithium (Eskalith, Lithobid) Mustargen (Mechlorethamine) Oxycontin (Oxycondone) Lithobid (Eskalith, Lithium) Mutamycin (Mitomycin) Oxygen Lodosyn (Carbidopa) Myleran (Busulfan) Lomustine (CeeNu) Mycophenlote Mofetil (Cellcept) P Lopinavir (Kaletra, Ritonavir, Mylotarg (Gemtuzumab Parlodel (Bromocriptine)–if used Norvir) Ozogamicin) for Parkinson’s Loxapine (Loxitane) Myochrysine (Gold Shots) Parsidol–if used for Parkinson’s Loxitane (Loxapine) Mytelase (Ambenonium Parsitan (Profenamine Ludiomil (Maprotiline) Hydrochloride) Hydrochloride) Lupron (Leuprolide) Pavabid Lusadril N Pentam 300 (Nebupent, Luvox (Fluvoxamine) Namenda Pentamidine) Lysodren (Mitotane) Navane (Thiothixene) Pentamidine (Nebupent, Pentam Nebupent (Pentamidine, Pentam 300) M 300) Pentoxifylline (Trental) Maprotiline (Ludiomil) Nelfinavir (Viracept) Pergolide (Permax) Marinol (Dronabinol) Neoscar (Cyclophamide, Cytoxan) Permax (Pergolide) Matulane (Procarbazine) Neostigmine (Prostigmin) Perphenazine (Trilafon) Mechlorethamine (Mustargen) Neupogen (Filgrastim) Platinol (Cisplatin) Megace (Megestrol) Nevirapine (Viramune) Plaquenil (Hydroxchloroquine) Megestrol (Megace) Nilandron (Nilutamide) Pletal (Cilostazol) Mellaril (Thioridazine) Niloric (Dihydroergotoxine) Plicamycin (Mithracin) Melphalen (Alkeran) Nilutamide (Nilandron) Pramipexole Dihdrochloride Memantine Hydrochloride Nitro-Dur (Deponit, Minitran, (Mirapex) (Namenda) Nitroglycerin, Nitro patch, Prednisone–if used for arthritis or Mentane Nitrostat) chronic lung disorders Mercaptopurine (Purinethol) Nitroglycerin (Deponit, Minitran, Procarbazine (Matulane) Mesoridazine (Serentil) Nitro Dur, Nitro patch, Procrit (Epoetin Alfa Epogen, Mestinon (Pyridostigmine) Nitrostat) Epogen) Methadone (Dolophine) Nitro Patch (Deponit, Minitran, Prochlorperazine (Compazine)–if Methdose Nitro-Dur, Nitroglycerin, used for psychotic disorders Methotrexate (Rheumatrex) Nitrostat) Procyclidine Hydrochloride Mexate Nitrostat, (Deponit, Minitran, Nitro (Kemadrin, Hydrochloride Miacalcin (Calcitonin)–if
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,540,564 Bodor (45) Date of Patent: Sep
    United States Patent (19) 11 Patent Number: 4,540,564 Bodor (45) Date of Patent: Sep. 10, 1985 54 BRAIN-SPECIFICDRUG DELIVERY 57 ABSTRACT 75 Inventor: Nicholas S. Bodor, Gainesville, Fla. The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug 73) Assignee: University of Florida, Gainesville, species to the brain, are: Fla. (a) compounds of the formula 21 Appl. No.: 516,382 22 Filed: Jul. 22, 1983 D-DHC) (I) Related U.S. Application Data wherein D is a centrally acting drug species, and 63 Continuation-in-part of Ser. No. 379,316, May 18, DHC is the reduced, biooxidizable, blood-brain 1982, Pat. No. 4,479,932, Ser. No. 461,543, Jan. 27, barrier penetrating lipoidal form of a dihydropyri 1983, , and Ser. No. 475,493, Mar. 15, 1983, , said Ser. dine - pyridinium salt redox carrier, with the No. 46,543, and Ser. No. 475,493, each is a continua proviso that when DHC) is tion-in-part of Ser. No. 379,316. 30 Foreign Application Priority Data O May 12, 1983 WO, PCT Int'l Appl. ......... WO83/00725 May 16, 1983 ICA) Canada ................................... 42892 51) Int. Cl...................... A61K 49/00; A61K 31/58; r’sN CO7J 17/00 52 U.S. Cl. ..................................... 424/9; 260/239.5; R 514/176 58 Field of Search .................. 424/9, 241; 260/239.5 wherein R is lower alkyl or benzyl and D is a drug species containing a single NH2 or OH func 56 References Cited tional group, the single OH group when present U.S.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Recent Advances in the Treatment of Parkinson's Disease
    Recent advances in the treatment of Parkinsonism Parkinsons disease RICHARD J. MARTOCCI, D.O. Highland Park, Michigan ticholinergic drugs conventionally used to treat par- kinsonism, levodopa was three-and-a-half times as Although there are both medical and effective in relieving symptoms. However, the surgical methods of treating treatment of paralysis agitans, whether medical or parkinsonism, medical therapy should surgical, remains purely palliative and never is cura- be tried first and surgical measures tive. reserved for patients who do not respond. Anticholinergic drugs may be Pathophysiologic and biochemical aspects combined with an antihistamine when The pathologic alterations in parkinsonism the symptoms are mild, and levodopa (paralysis agitans) most consistently affect the zona used alone or with another drug when compacta2 of the substantia nigra with formation of the disease is moderate to severe. The Lewy bodies, or inclusion bodies, and neurofibril- side effects of levodopa are lary tangles3 such as those in Alzheimers disease and troublesome, and the clinical program other forms of senile atrophy. Histochemical studies must be adjusted constantly to achieve using fluorescent techniques have shown that maximum benefits and minimum side dopamine is almost nonexistent in the neostriatum effects. Pyridoxine reverses side effects and substantia nigra. Dopamine, a catecholamine, but also the benefits of levodopa. Use of has proved to be a neurohumeral transmitter. This a peripheral decarboxylase inhibitor suggests that in parkinsonism there is a decrease in may permit reduction in the dose of ability of affected brain tissue to form dopamine, levodopa to a point that side effects can and from 80 to 90 percent of dopamine in the brain be minimal.
    [Show full text]
  • Medicinal Chemistry Unit
    JAIPUR COLLEGE OF PHARMACY, JAIPUR B.PHARMACY, SECOND YEAR, FOURTH SEMESTER MEDICINAL CHEMISTRY-I Prepared by: Mrs. Nisha Dhir UNIT-III Cholinergic and Anticholinergic Drug The nervous system is divided into the somatic nervous system, which controls organs under voluntary control (mainly muscles) and the autonomic nervous system (ANS) which regulates individual organ function and homeostasis, and for the most part is not subject to voluntary control. The autonomic nervous system is also known as the visceral or automatic system. The ANS is predominantly an efferent system transmitting impulses from the central nervous system (CNS) to peripheral organ systems. The autonomic nervous system consists of sensory neurons and motor neurons that innervates between the central nervous system (especially the hypothalamus and medulla oblongata) and various internal organs such as the : heart, lungs, viscera, glands (both exocrine and endocrine). Thus it is responsible for monitoring conditions in the internal environment and bringing about appropriate changes in them. The ANS is divided into two separate divisions called the parasympathetic and sympathetic systems, on the basis of anatomical and functional differences. Both of these systems consist of myelinated preganglionic fibres which make synaptic connections with unmyelinated postganglionic fibres, and it is these which then innervate the effector organ. These synapses usually occur in clusters called ganglia. The main nerves of the parasympathetic system are the tenth cranial nerve, the vagus nerve, which originate in the medulla oblongata. Other preganglionic parasympathetic neurons also extend from the brain as well as from the lower tip of the spinal cord. Each preganglionic parasympathetic neuron synapses with just a few postganglionic neurons, which are located near or in the effector organ, a muscle or major gland.
    [Show full text]
  • HMSA DRUG FORMULARY - Listed Alphabetically by GENERIC Name Rev
    HMSA DRUG FORMULARY - Listed alphabetically by GENERIC name Rev. 10/1/04 - Page 1 Ther. Generic Brand Select Select Choice Choice QUEST QUEST- CCS Child- Categ. Net ren's Code Code Footnote Code Footnote G = Generic. P = Preferred. O = Other brand. X = Covered. If a number appears next to alpha code, see last page for footnote text. 17 abacavir sulfate Ziagen P O X 17 abacavir/ lamivudine/ zidovudine Trizivir P O X 141 acarbose Precose P P X 50 acebutolol -- G G 50 acebutolol Sectral O O 65 acetaminophen -- X 40 acetazolamide -- G G X 40 acetazolamide Diamox O O 107 acetazolamide -- G G X 107 acetazolamide Diamox O O 40 acetazolamide, extended release Diamox Sequels P O X 239 acetic acid in aluminum acetate -- G G X 239 acetic acid in aluminum acetate Domeboro Otic O O 238 acetic acid, otic -- G G X 238 acetic acid, otic VoSol O O 238 acetic acid/ hydrocortisone, otic -- G G X 238 acetic acid/ hydrocortisone, otic VosSol HC O O 144 acetohexamide -- G G X 144 acetohexamide Dymelor O O 267 acetohydroxamic acid Lithostat O O 99 acetylcarbromal Paxarel O O 198 acetylcysteine -- G G X 198 acetylcysteine Mucomyst O O 243 acitretin Soriatane P O X 255 aclometasone dipropionate 0.05%, cream/ ointment Aclovate O O 173 activated charcoal -- X 22 acyclovir -- G G X 22 acyclovir Zovirax O O 248 acyclovir ointment Zovirax P O X 240 adapalene Differin P 10 O 10 X 10 24 albendazole Albenza O O 188 albuterol -- G G X 188 albuterol Proventil O O 188 albuterol Ventolin O O 189 albuterol -- G G X 189 albuterol Proventil P O X 189 albuterol Proventil HFA O O 189 albuterol Ventolin P O X 189 albuterol Ventolin HFA O O 188 albuterol, extended release -- G G X 188 albuterol, extended release Volmax O O 189 albuterol/ ipratropium Combivent P O X HMSA DRUG FORMULARY - Listed alphabetically by GENERIC name Rev.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]